Radiotherapy is a cornerstone of modern oncology, traditionally viewed as a localized tool to destroy tumor mass. However, this local intervention triggers a profound systemic paradox: while aiming to eradicate a tumor, radiation frequently cripples the patient's systemic immune system.
This treatment-induced immunosuppression is primarily driven by radiation-induced lymphopenia (RIL)—a severe depletion of circulating lymphocytes. Understanding and mitigating RIL has become one of the most critical frontiers in oncology, particularly because the success of modern immunotherapies depends entirely on a functional, intact immune population.
The Bloodstream as a Moving Target
To understand why a localized beam of radiation causes systemic immune depletion, we must look at the extreme radiosensitivity of immune cells and the dynamics of blood circulation.
Circulating lymphocytes are uniquely fragile; they undergo apoptosis at radiation doses as low as 4 Gy (Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach). While a tumor might require 60 Gy to destroy, the healthy lymphocytes passing through the treatment field are decimated by minor, low-dose scatter radiation.
Because blood continuously circulates throughout the body, a localized radiation beam acts as a systemic filter. Over a standard multi-week, multi-fraction course of radiotherapy, a massive proportion of the body's total blood volume passes through the target field. As Yanshuang Cheng et al. note in their study on head and neck cancers, broad-field radiation inadvertently purges this circulating immune pool, creating a physiological barrier that can completely counteract the benefits of subsequent immunotherapies (Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy).
Consequently, machine learning models have revealed that the total volume of tissue irradiated is often a far more powerful predictor of immune depletion than the peak radiation dose delivered to the tumor center (Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach).
Anatomical Vulnerabilities: Spleen and Pericardium
The severity of RIL is heavily dictated by where the radiation is directed, particularly when the treatment field overlaps with major vascular hubs or secondary lymphoid organs.
[Radiation Beam] ───► [Spleen / Pericardium] ───► [Low-Dose Scatter (e.g., V5)] ───► [Massive Lymphocyte Apoptosis] ───► Systemic RIL
The Spleen
The spleen acts as the body's primary reservoir and filtering station for lymphocytes. Despite its immunological importance, the spleen has historically not been classified as an "organ at risk" (OAR) during abdominal radiotherapy planning. Recent work by Yifu Ma et al. demonstrates that the maximum dose ($D_{max}$) and the volume of the spleen receiving at least 5 Gy ($V_5$) are directly proportional to the drop in a patient's absolute lymphocyte count (The relationship between splenic dose and radiation-induced lymphopenia). When the spleen receives unconstrained scatter radiation, it effectively becomes a death trap for the systemic lymphocyte pool.
The Pericardium
In thoracic malignancies, such as esophageal cancer, the heart and its surrounding pericardium receive high volumes of blood flow. Xiaoman Tian et al. established that higher radiation doses delivered to the pericardium are strongly associated with severe, grade 4 lymphopenia (Pericardial irradiation dose may be strongly associated with grade 4 lymphopenia and affect prognosis in patients with locally advanced esophageal cancer receiving definitive concurrent chemoradiotherapy). Sparing these highly vascularized structures is essential to preventing systemic immune collapse.
Microenvironmental and Signaling Suppression
Radiation does not merely kill lymphocytes through direct exposure; it also reprograms the tumor microenvironment (TME) and intracellular pathways to actively suppress immune recovery.
- Macrophage Recruitment: High-dose radiotherapy can paradoxically trigger tumor cells to produce Macrophage Colony-Stimulating Factor (MCSF). As detailed by Zhiyun Liao et al., this cascade recruits regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) to the tumor site, transforming the TME into an immunosuppressive zone that dampens long-term anti-tumor immunity (Targeting the Cascade Amplification of Macrophage Colony-stimulating Factor to Alleviate the Immunosuppressive Effects Following Radiotherapy).
- Intracellular Signaling Disruption: Even when using highly targeted radionuclide therapies, radiation can suppress surviving T-cells by interfering with critical intracellular signaling pathways. The authors of a recent cellular oncology study demonstrated that radionuclide exposure disrupts the phosphorylation of AKT ($p\text{-AKT}$) and ERK ($p\text{-ERK}$), which are vital for T-cell activation, survival, and proliferation (Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects).
This multi-layered depletion mirrors other forms of clinical immunosuppression, such as the surgical stress that depletes dendritic cells (Di Wang et al.), chemotherapy-induced damage to the spleen and thymus (Purification, structural characterization and immunological activity of Sibiraea laexigata (L.) Maxim polysaccharide), or viral-mediated CD4 depletion (Mathias Bruyand et al.). In all cases, the loss of these cellular subsets leaves patients highly vulnerable, severely reducing their ability to mount humoral or cellular defenses (Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis).
Clinical Strategies for Lymphocyte Preservation
To overcome the barrier of RIL, researchers have developed several concrete dosimetric, temporal, and biological strategies designed to protect the immune system during cancer treatment.
1. Dosimetric Sparing and Field Optimization
The most immediate solution lies in changing how radiation plans are designed. By transitioning from elective-nodal irradiation (which prophylactically targets wide lymphatic networks) to involved-field irradiation (which strictly targets known tumor volumes), clinicians can drastically reduce the volume of healthy tissue and blood exposed to radiation (Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer). Furthermore, explicitly introducing splenic dose constraints—specifically limiting the spleen $V_5$ to minimal volumes—directly mitigates the incidence of severe lymphopenia (Clinical Considerations of Splenic Dose Constraints to Mitigate Radiation‐Induced Lymphopenia).
2. Proactive Immune Cell Harvesting
When radiation must be paired with advanced cellular therapies like Chimeric Antigen Receptor (CAR) T-cell therapy, the temporal sequencing of treatment is paramount. Hui Shi demonstrated that collecting a patient's peripheral blood mononuclear cells prior to administering whole-brain radiotherapy completely insulates the baseline lymphocyte population from the lymphotoxic effects of the upcoming radiation (Whole brain radiotherapy combined with CART-cell therapy for relapsed/refractory central nervous system B-cell lymphoma). This ensures that high-quality, undamaged cells are available for manufacturing the therapeutic payload.
3. Multimodal and Biological Rescue
Rather than relying on high-dose radiation alone, emerging protocols utilize multimodal radiotherapy. This approach combines localized high-dose radiotherapy (HDRT) to ablate the primary tumor with low-dose radiotherapy (LDRT) to safely reprogram the surrounding microenvironment without killing infiltrating immune cells (Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors).
Additionally, combining radiation with targeted small-molecule inhibitors—such as MCSF blockers or HPK1 inhibitors—can prevent the recruitment of suppressive cells and rescue the $p\text{-AKT}$ and $p\text{-ERK}$ pathways in surviving T-cells (Targeting the Cascade Amplification of Macrophage Colony-stimulating Factor to Alleviate the Immunosuppressive Effects Following Radiotherapy; Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects).
Ultimately, a patient's ability to achieve an immune "rebound" post-radiotherapy serves as an independent biomarker for survival (Effectiveness and mechanisms of lymphocytes at different time points in predicting consolidation immunotherapy following adaptive chemoradiotherapy in locally advanced non-small cell lung cancer). By treating the immune system as an organ at risk, modern radiotherapy protocols aim to destroy the tumor while leaving the patient's natural defenses intact to finish the job.
Key Foundational Work
A short-term increase of the postoperative naturally circulating dendritic cells subsets in flurbiprofen-treated patients with esophageal carcinoma undergoing thoracic surgery (2016) — contributed 1 concept elements to this direction.
Immunodeficiency, HIV RNA plasma viral load and risk of AIDS-defining and non-AIDS-defining neoplasia, ANRS CO3 Aquitaine Cohort (1998–2006) (2009) — contributed 1 concept elements to this direction.